sar425899 dual agonist glp-1 glucagon sanofi Emerging incretin- and multi- agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond The Road GIPR/GLP-1R dual agonist therapies no-glp1 Size:1 Pack

sar425899 dual agonist glp-1 glucagon sanofi Emerging incretin- and multi- agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond The Road GIPR/GLP-1R dual agonist therapies no-glp1 Size:1 Pack

GIPR/GLP-1R dual agonist therapies for diabetes and weight loss– Chemistry, Physiology and Clinical application - PMC

doi: 10.1016/S2213-8587(19)30249-9 35 LeeJ

no-glp1

Size:1 Pack

The SEQUEL trial, a 52-week extension, indicated sustained weight loss over two years, with reductions of 9.3% and 10.5% from baseline for the 7.5/46 mg and 15/92 mg doses, respectively [34]